Introduction Limitations in the data used to define thromboprophylaxis for patients with
antiphospholipid antibodies (aPLAbs) and thrombosis include uncertainties after an initial …

Background Few data are available on thrombotic outcomes during pregnancy and
puerperium occurring after an initial provoked venous thromboembolic (VTE) event …

BACKGROUND: Combined oral contraceptives (COC) increase the risk of venous
thromboembolism (VTE), but the risk of recurrent VTE is not precisely determined. In this …

Background. It is established that combined oral contraceptive (COC) treatment increases
the risk of a pulmonary embolism (PE), but specific risk factors for a fatal outcome from a PE …

Objective Antiphospholipid syndrome (APS) is a systemic autoimmune disorder
characterised by venous thrombosis (VT) or arterial thrombosis (AT) and/or pregnancy …

Antiphospholipid syndrome (APS) is an autoimmune condition characterized by thrombosis
and pregnancy morbidity. 1 Thrombotic APS variably involves arterial, venous, and …

2. Andreoli L, Chighizola CB, Banzato A, et al. Estimated frequency of antiphospholipid
antibodies in patients with pregnancy morbidity, stroke, myocardial infarction, and deep vein …

Introduction Antiphospholipid syndrome (APS) is a major acquired thrombophilia in which
vascular thrombosis (venous or arterial) and/or pregnancy losses occur. Despite the use of …

Background Antiphospholipid syndrome (APS) is an acquired thrombophilia disorder with
prevalence not completely known in patients with first unprovoked venous thromboembolic …

BACKGROUND: Anti-phospholipid antibody syndrome (APS) is an autoimmune
thrombophilic syndrome characterized by venous and arterial thromboembolic disease …